A majority of human colon carcinomas coexpress the epidermal growth factor (EGF)-related peptides transforming growth factor a (TGFa), amphiregulin (AR) and CRIPTO-1 (CR). We have synthesized novel, antisense mixed backbone oligonucleotides (AS MBOs) directed against TGFa, AR and CR. We screened the EGFrelated AS MBOs for their ability to inhibit the anchorage independent growth of GEO human colon carcinoma cells. The MBOs that showed a high in vitro ecacy were then used for in vivo experiments. TGFa, AR and CR AS MBOs were able to inhibit the growth of GEO tumor xenografts in nude mice in a dosedependent manner. Furthermore, the AS MBOs were able to speci®cally inhibit the expression of the target mRNAs and proteins in the tumor xenografts. A more signi®cant tumor growth inhibition was observed when mice were treated with a combination of the three AS MBOs as compared to treatment with a single AS MBO. Finally, tumors from mice treated with TGFa, AR and CR AS MBOs showed a signi®cant reduction of microvessel count, as compared with tumors from untreated mice or from mice treated with a single AS MBO. These data suggest that combinations of AS oligonucleotides directed against dierent growth factors might represent a novel, experimental therapy approach of colon carcinomas.
Introduction
Human colon cancer cells secrete and/or respond to several dierent growth factors, that can regulate their proliferation through autocrine, paracrine and/or juxtacrine pathways (Salomon et al., 1995) . Several studies have demonstrated that the epidermal growth factor (EGF)-related peptides transforming growth factor a (TGFa), amphiregulin (AR) and CRIPTO-1 (CR) might play an important role in the pathogenesis of human colon carcinoma (Salomon et al., 1995) . TGFa and AR bind and activate the EGF receptor (MassagueÂ , 1990; Shoyab et al., 1989) . Approximately 50 ± 90% of colon tumors express TGFa (Salomon et al., 1995) . Coexpression of TGFa and the EGF receptor has been detected in the majority of human primary carcinomas and colon cancer cell lines, suggesting that an autocrine loop involving TGFa and the EGF receptor is present in colon carcinoma cells (Salomon et al., 1995) . AR protein and mRNA have been found to be overexpressed in approximately 50% of human primary colon carcinomas and in several colon carcinoma cell lines (Salomon et al., 1995; Ciardiello et al., 1991; Saeki et al., 1992) . Furthermore, AR protein is preferentially expressed in well dierentiated human primary colon carcinomas when compared with poorly dierentiated tumors . Nuclear localization of AR has been described in colon and breast carcinoma cell lines and human primary carcinomas (Ciardiello et al., 1991; Saeki et al., 1992; Johnson et al., 1992; Gagliardi et al., 1994; Normanno et al., 1993 Normanno et al., , 1994 . In this regard, AR possess a nuclear targeting sequence, and it has been shown that exogenously applied AR associates with nuclei in a time and concentration dependent fashion (Shoyab et al., 1989; Modrell et al., 1992) . High levels of CR mRNA and protein were found in a majority of human colon carcinoma cell lines and in 60 ± 70% of human primary and metastatic colorectal tumors (Ciardiello et al., 1991; Saeki et al., 1992) . CR does not directly bind to the EGF receptor, nor to the erb B-2, erb B-3 or erb B-4 tyrosine kinases (Kannan et al., 1997; Brandt et al., 1994) . However, a CR recombinant protein was able to enhance the tyrosine phosphorylation of shc and to increase p42 erk-2 mitogen-activated protein kinase (MAPK) activity in mammary epithelial cells (Kannan et al., 1997) . More recently, it has been demonstrated that CR can enhance the phosphorylation of the p85 regulatory subunit of phosphatidylinositol 3'-kinase (PI3K) and transiently induce the phosphorylation of AKT (Ebert et al., 1999) .
Coexpression of multiple growth factors of the EGF family occurs in colon carcinoma cells in vivo and in vitro (Salomon et al., 1995; Ciardiello et al., 1991; Saeki et al., 1992) . For example, the well dierentiated colon carcinoma cell line GEO expresses moderate levels of TGFa, AR and CR mRNAs and proteins (Ciardiello et al., 1991; Saeki et al., 1992) . Coexpression of CR and AR proteins was also observed in about 50% of the carcinomas and adenomas examined . Furthermore, it has been recently demonstrated that auto-and cross-induction among several growth factors of the EGF family occurs in colon carcinoma cells (Barnard et al., 1994) . This redundancy is not unique to colon cancer cells, since it also occurs in human breast, ovarian and lung cancer cells Normanno et al., 1993 Normanno et al., , 1995a Panico et al., 1996; Fontanini et al., 1998; Stromberg et al., 1994; Casamassimi et al., 2000) .
Direct evidence that TGFa, AR and CR can function as autocrine growth factors in colon carcinoma cells in vitro has been established by using either neutralizing monoclonal antibodies or by utilizing antisense phosphorothioate oligodeoxynucleotides (AS PS-oligos), or antisense mRNA retroviral expression vectors directed against these growth factors (Sizeland and Burgess, 1992; Watkins et al., 1991; Ciardiello et al., 1993 Normanno et al., 1995b Normanno et al., , 1996 . The present study was designed to evaluate the role of TGFa, AR and CR in the in vivo growth of human GEO colon carcinoma cells, and to assess whether these EGF-related peptides might represent suitable targets for experimental therapy of human colon carcinoma. For this purpose, novel, mixed backbone AS oligos directed against the EGF-related growth factors were synthesized. Several antisense sequences were screened by using in vitro assays. Oligonucleotides with high in vitro antitumor ecacy were selected for the in vivo studies.
Results
We have previously demonstrated that AS PS-oligos directed against TGFa, AR and CR are able to inhibit the in vitro anchorage independent growth (AIG) of GEO colon carcinoma cells Normanno et al., 1995b Normanno et al., , 1996 . We developed novel, antisense mixed backbone oligonucleotides (AS MBOs) directed against the EGF-related growth factors, starting from the sequence of the above mentioned AS PS-oligos (Table 1) . The AS PS-Oligos directed against either TGFa (OSD-a1), AR (OSD-AR1) or CR (OSD-CR1 and OSD-CR2) were able to inhibit the AIG of GEO cells in a dose dependent manner (Figure 1a ± c) . An approximately 50% growth inhibition was observed when cells were treated with 0.5 mM of the AS PS-oligos. However, the OSD-a1 contains a sequence of four G (G quartet) in the middle (Table 1) . This sequence has been reported to form hyperstructures that can be responsible for potential non-speci®c growth inhibition (Agrawal, 1996) . We therefore synthesized several dierent TGFa AS oligos lacking the G quartet. These molecules showed a much lower anti-proliferative activity when compared with the OSD-a1 oligo (data not shown). Therefore, we synthesized two dierent MBOs oligos: the OSD-a2, that has the same oligonucleotide sequence of the OSD-a1, and the OSD-a3, in which the G quartet was disrupted by substitution of a G nucleotide with inosine (Table 1) . This modi®ed TGFa AS oligo was able to inhibit the proliferation of GEO cells, and it was nearly equipotent to the TGFa AS oligos with the G quartet (OSD-a2 and OSD-a1) when used at equimolar concentrations (Figure 1a) . These results suggest that the anti-proliferative activity of the OSDa1 and of the OSD-a2 is speci®c, and it is not due to the presence of the G quartet. Analogously, the 20-mer AR AS oligo OSD-AR1 carries a G-quartet at the 5' end. A 19-mer AR AS PS-oligo (OSD-AR2) and a corresponding 19-mer AR AS MBO (OSD-AR3), both lacking the 5' G-quartet, were as ecient as the OSD-AR1 in inhibiting GEO cells AIG (Figure 1b) . Finally, two dierent CR AS PS-oligos were able to inhibit the AIG of GEO cells (OSD-CR1 and OSD-CR2). The MBOs derived from these sequences, respectively OSD-CR3 and OSD-CR4, were equipotent to the corresponding PS-oligos in inhibiting the AIG of GEO cells ( Figure 1c ). No signi®cant growth inhibition was observed when GEO cells were treated with similar concentrations of the scramble OSD-NNN MBO, that is a mixture of 4 18 dierent oligos (Agrawal, 1996) (Figure 1a ± c) . The anti-proliferative eects of the AR, TGFa and CR MBOs were reversed when GEO cells were simultaneously treated with the corresponding recombinant growth factor (Figure 1d ). Furthermore, we found that the AR AS MBO, OSD-AR3, did not inhibit the anchorage-dependent growth of SK-Br-3 breast carcinoma cells, that do not express AR (De Luca et al., 1999 and data not shown). Analogously, the anti-CR OSD-CR4 had no eect on the growth of OVCA-429 human ovarian carcinoma cells, that do not express CR (Casamassimi et al., 2000 and data not shown).
The AS MBOs were able to speci®cally inhibit the synthesis of AR, CR or TGFa proteins in GEO cells. The following speci®c bands were detected in GEO cells following Western blot analysis of whole cell lysates: a 24 kDa, cell associated precursor form of AR ( Figure 2a) ; a 37 kDa CR protein ( Figure 2b) ; and a 30 kDa TGFa protein, that corresponds to the cell associated pro-TGFa (Figure 2c ). Treatment of GEO cells with OSD-AR3, OSD-CR4 or OSD-a2 MBOs at a concentration of 1 mM for 48 h resulted in an approximately 50% reduction respectively of AR, CR and TGFa protein expression, as assessed by densitometric analysis of the ®lms shown in Figure 2a ± c. The OSD-NNN control MBO at the same concentration had no signi®cant eect upon the levels of endogenous growth factors (Figure 2a ± c) .
The MBOs selected by using the in vitro assays were then used for the in vivo experiments. GEO cells were injected subcutaneously into the dorsal¯ank of nude mice. When the tumor size was approximately 0.2 cm 3 , 10 mice per group were treated intraperitoneally ®ve times a week for 4 weeks with dierent concentrations of EGF-related AS MBOs. As shown in Figure 3 , a signi®cant, dose dependent, tumor growth inhibition 
The underlined and bold sequences are 2'-Omethyl RNA PS, others are DNA PS. In the ISD-a3, the bold I indicates a substitution of G with I in the G-quartet. Untreated GEO xenografts in nude mice express high levels of TGFa, AR and CR proteins, as assessed by immunohistochemistry. Staining for TGFa, AR and CR was mostly localized in the cytoplasm, although nuclear staining for AR was occasionally observed (Figure 4a , c and e). Para-nuclear staining of CR was also occasionally found, as previously described (Gagliardi et al., 1994) . Staining with these antibodies could be blocked by pre-incubation with the corresponding recombinant protein (data not shown). A signi®cant reduction of AR, CR and TGFa protein expression was observed in tumors from mice that were treated with the corresponding AS MBOs (Figure 4b , d and f). In particular, both a reduction of the per cent of stained cells and of the intensity of staining was found following treatment of the mice with 6 mg/kg of either AR, CR or TGFa AS MBOs (Table 2) .
Semi-quantitative RT ± PCR was performed to establish whether antisense treatment could speci®cally reduce AR, CR or TGFa mRNA levels in GEO tumor xenografts. The levels of either CR, AR or TGFa mRNA were determined by RT ± PCR and Southern blot analysis in antisense or missense treated, and in untreated GEO tumor xenografts. Serial dilutions (4 ± 6) of cDNAs from antisense or missense treated, and from untreated tumors were analysed, in order to reach non-saturating concentration of the ®nal PCR product (Figure 5a ± c and data not shown). AR, CR and TGFa mRNA content was normalized by GAPDH values, that showed dierences 510% between corresponding dilutions (data not shown). Finally, the data were expressed as per cent of control content of the speci®c mRNA ( Figure 5d ). GEO tumor xenografts showed a signi®cant reduction in the levels of AR, CR and TGFa mRNAs following treatment with the speci®c AS MBOs (Figure 5a ± c). In particular, a 55, 60 and 52% reduction respectively of TGFa, AR and CR mRNA levels was observed in antisense treated tumors when compared to control untreated tumors (Figure 5d ). Missense treatment did not signi®cantly aect either TGFa, AR or CR mRNA expression in GEO tumor xenografts ( Figure  5d ).
We next assessed the levels of phosphorylated p42/ p44 MAP kinase in GEO tumors from untreated and Figure 1 In vitro screening of TGFa (a), AR (b) and CR (c) AS oligonucleotides. GEO cells (5610 3 cells/well) were seeded in 0.3% Difco Bactoagar supplemented with complete culture medium. 0.5 ml of this suspension was layered over 0.5 ml of 0.8% agar-medium base layer in 24-multiwell cluster. The cells were treated 2 h and 5 days after seeding with the indicated concentrations of AS oligonucleotides. After 14 days the colonies were stained with nitroblue tetrazolium, and colonies larger than 50 mm were counted with a colony counter. (d) Reversion of AS MBOs eects by recombinant growth factors. GEO cells were seeded as described above, and treated as follows: with 0.5 mM OSD-a3, or with 0.5 mM OSD-a3 plus 1 nM recombinant TGFa; with 0.5 mM OSD-AR3, or with 0.5 mM OSD-AR3 plus 1 nM recombinant AR; with 0.5 mM OSD-CR4, or with 0.5 mM OSD-CR4 plus 100 ng/ml recombinant CR AS treated mice by Western blot analysis (Figure 2d ). We found that treatment with OSD-a2 or with OSD-AR3 MBOs (10 mg/kg) determined respectively an approximately 75 and 45% reduction of the levels of phosphorylated MAP kinase when compared with tumors from untreated mice, as assessed by densitometric analysis of the ®lm shown in Figure 2d . However, treatment of the mice with the OSD-CR4 MBO only induced a slight reduction (15%) of the levels of phosphorylated MAP kinase when compared with untreated mice. No signi®cant dierences in the levels of MAP kinase between treated and untreated mice were observed, as assessed by using an anti-p42/ p44 MAP kinase antibody (data not shown). Finally, immunohistochemical analysis of tumors from treated and untreated mice was performed by using an antiphospho p42/p44 MAP kinase antibody. This analysis showed an evident reduction of the number of stained carcinoma cells in tumors from mice treated with the OSD-a2 or with OSD-AR3 MBOs as compared with tumors from untreated mice, thereby con®rming the results of the Western blot analysis (data not shown).
GEO cells coexpress AR, CR and TGFa. We have previously shown that a supra-additive eect occurred when GEO cells were treated with a combination of two dierent AS oligos directed against AR, CR or TGFa (Normanno et al., 1996) . However, the AIG of GEO cells was almost completely suppressed when cells were treated with a combination of the three AS Soligos (Normanno et al., 1996) . Similar results were obtained with the EGF-related MBOs (data not shown). For this reason, we chose to use the latter combination in the in vivo experiments. In this regard, a more signi®cant tumor growth inhibition was observed when mice were treated with a combination of the three AS MBOs as compared to treatment with a single AS MBO (Figure 2d ). This dierence was statistically signi®cant when growth inhibition after 28 days of treatment was compared by using Student's ttest (P50.02 for each AS oligo vs combination). Speci®cally, an 80% tumor growth inhibition was observed when mice were treated with a combination of OSD-a2, OSD-CR4 and OSD-AR3 at a total concentration of 10 mg/kg for 28 days.
Mice were sacri®ced when tumors reached a volume higher than 2 cm 3 . Mice that were not treated, or that were treated with the missense oligonucleotide (OSD-NNN) were sacri®ced 28 days after starting the treatment. After termination of treatments on day 28, GEO tumors in AS treated mice resumed a growth rate slightly lower as compared to that of controls. Tumors in mice treated with a single oligo reached an approximately 2 cm 3 volume 56 days after starting the treatment, while tumors in mice treated with the combination of the three AS MBOs reached a similar volume by day 63.
Finally, microvessel count (MVC), an indicator of neoangiogenesis, was determined in untreated and antisense treated GEO xenografts by staining of endothelial cells with an anti-Factor VIII antibody. We found that treatment of mice with either anti-CR, anti-AR or anti-TGFa MBO at a 10 mg/kg dose, produced a slight decrease of neoangiogenesis in GEO xenografts (Table 3) . Actually, only treatment with the OSD-AR4 MBO produced a statistically signi®cant reduction of MVC in GEO tumors as compared with tumors from untreated mice (P=0.005; Student's ttest) (Table 3) . However, a more signi®cant reduction of MVC was observed following treatment of mice with a combination of the three AS MBOs at a total dose of 10 mg/kg, as compared with tumors from untreated mice or from mice treated with a single AS MBO (P50.001 for all comparisons; Student's t-test).
Discussion
EGF-related growth factors such as TGFa, AR and CR are involved in the pathogenesis of human colon carcinoma, and therefore may represent suitable targets for experimental therapy of human colon carcinoma (Salomon et al., 1995) . In this regard, this study is the ®rst to demonstrate that AS oligos directed against TGFa, AR and CR are able to inhibit the in vivo growth of human colon carcinoma cells. In fact, a signi®cant, dose-dependent reduction of GEO tumor growth was observed when mice were treated with AR, TGFa and CR AS oligos. We found that the AR, CR and TGFa AS oligos were nearly equipotent in inhibiting the in vitro and in vivo growth of GEO cells. In fact, GEO cells express high levels of TGFa, AR and CR proteins. However, we have previously described that in several ovarian and breast carcinoma cell lines there is a reasonable correlation between levels of expression of the target growth factor and the relative ecacy of the AS PS-oligos to block proliferation (De Luca et al., 1999; Casamassimi et al., 2000) . Similar results were obtained with the EGFrelated MBOs (data not shown). The above-mentioned data are consistent with several previous reports. In fact, it has been previously shown that GEO cells transfected with a CR antisense expression vector formed tumors in nude mice that were signi®cantly smaller as compared with GEO parental cells . Infection of GEO cells with an inducible TGFa antisense expression vector did not result in a signi®cant reduction of GEO tumor growth in nude mice (Ciardiello et al., 1993) . A low level of expression of the TGFa antisense expression vector might explain these results. Finally, no data are available on the role of AR in the in vivo growth of human colon carcinoma cells. However, a signi®cant reduction of GEO tumor growth in nude mice was observed following treatment of mice with an EGF-receptor blocking monoclonal antibody . These data suggest that an autocrine loop involving the EGF receptor and its ligands is important in sustaining the in vivo growth of human GEO colon carcinoma cells.
AS PS-oligos directed against growth factors or signal transduction proteins have been successfully used to inhibit the in vitro and in vivo growth of several human carcinoma cell lines (Neckers et al., 1992; Gibbs, 2000) . More importantly, AS PS-oligos directed against ras, raf, Protein Kinase C (PKC) and Protein Kinase A (PKA), are in Phase II clinical development (Gibbs, 2000; Agrawal, 1996) . However, toxicity studies have shown some dose-dependent side eects of conventional AS PS-oligos (Agrawal, 1996) . In particular, activation of complement and prolongation of activated partial thromboplastin time (aPTT) were observed in monkeys. Furthermore, side eects such as fatigue, fever, thrombocytopenia and elevation of transaminases have been observed in ongoing , 10 mice per group were treated intraperitoneally ®ve times a week, for 4 weeks, with the indicated doses of EGF-related AS MBOs. (d) Mice were treated with a combination of the three AS MBOs at a total dose of 10 mg/kg, or with 10 mg/kg of each AS MBO. Student's t-test was used to compare tumor size among dierent treatment groups and control untreated mice after 28 days of treatment. Tumor size in all treatment groups was signi®cantly dierent as compared with controls. Furthermore, the dierence between the tumor size in mice treated with a single oligo vs mice treated with a combination of the three AS MBOs was statistically signi®cant (P50.02 for each comparison; Student's t-test) human clinical trials with PS-oligos (Gibbs, 2000; Agrawal and Zhao, 1998b) . The polyanionic nature of PS-oligos is believed to be responsible for most of their nonsequence-speci®c activities (Agrawal, 1996; Agrawal and Zhao, 1998b) . More recently, MBOs were designed (Agrawal, 1996) . MBOs contain both phosphorothioate segments, and modi®ed oligodeoxyribonucleotide or oligoribonucleotide segments, either in the central portion (central modi®ed oligo) or at the 5' and 3' ends of the oligo (laterally modi®ed oligos). The advantages of MBOs over PS-oligos are increased biological activity, reduced polyanionic-related side eects and increased in vivo stability (Agrawal, 1996; Agrawal and Zhao, 1998a) . In this regard, we found that EGF-related, laterally modi®ed MBOs were very ecient in inhibiting in vivo tumor growth, and did not show any signi®cant toxic eects in nude mice. Laterally modi®ed MBOs have shown bioavailability following oral or rectal administration (Agrawal et al., 1998b; Wang et al., 1999) . Preliminary results suggest that oral administration of AR, CR and TGFa MBOs is also able to inhibit GEO tumor growth in nude mice (N Normanno, unpublished observations).
A majority of human colon carcinoma cell lines and primary human colon carcinomas coexpress several (Salomon et al., 1995; Ciardiello et al., 1991; . Coexpression of dierent EGF-like peptides is a general phenomenon in human carcinogenesis. In fact, co-expression of AR, CR and TGFa has been previously shown in primary human breast, lung and ovarian carcinomas, as well as in several dierent breast, ovarian and lung carcinoma cell lines Normanno et al., 1993 Normanno et al., , 1995a Panico et al., 1996; Fontanini et al., 1998; Stromberg et al., 1994; Casamassimi et al., 2000) . This coexpression suggests that each growth factor might perform a dierent function in regulating cell proliferation, dierentiation and transformation. In this regard, both AR and TGFa bind and activate the EGF receptor, while CR binds to a still unknown receptor which activates the ras/raf/ MEK/MAPK and the PI3K/AKT pathways (MassagueÂ , 1990; Shoyab et al., 1989; Kannan et al., 1997; Ebert et al., 2000) . We found that treatment of mice with either anti-TGFa or anti-AR AS MBOs determined a signi®cant reduction of the levels of phosphorylated p42/p44 MAP kinase in GEO tumors. In this respect, the TGFa AS MBO was more ecient as compared to the AR AS oligo. This dierence might be due to the higher anity of TGFa for the EGFreceptor as compared with AR (Shoyab et al., 1989) . However, only a slight reduction of the levels of phosphorylated p42/p44 MAP kinase was observed following treatment with the anti-CR MBO. It is possible that the growth inhibitory eect of the CR AS MBO is related to the blockade of the PI3K/AKT pathway in GEO cells (Ebert et al., 2000) . It is also conceivable that no signi®cant eects were observed on MAP kinase phosphorylation following treatment with the CR AS MBO because of the concomitant activation of the EGF receptor/MAP kinase pathway in CR AS treated cells by both TGFa and AR. A functional interaction between dierent EGFrelated growth factors might exist. In this respect, it has been demonstrated that several EGF-related peptides are able to induce the expression of other members of the same family in breast and colon carcinoma cells Barnard et al., 1994) . Therefore, it appears that a network of EGF-related peptides sustains the proliferation of colon carcinoma cells. This observation might provide an explanation for the more signi®cant growth inhibition observed when the expression of multiple growth factors is blocked by using a combination of AS oligos, as compared to when only the expression of a single growth factor is inhibited. We also found that concomitant blockade of AR, CR and TGFa resulted in a more signi®cant inhibition of neoangiogenesis as compared to treatment with a single AS MBO. It has long been established that EGF and TGFa are potent angiogenic mediators (Schreiber et al., 1986) . More recently, it has been demonstrated that AR is also involved in tumor vessels formation in human breast carcinoma xenografts (Ma et al., 1999) . In this regard, we found that treatment of GEO tumors with any of the EGF-related AS MBOs produced a slight reduction of MVC. However, a statistically signi®cant reduction of MVC in GEO tumors, as compared with tumors from untreated mice, was only observed following treatment with the OSD-AR4 MBO. These results might suggest a predominant role of AR in inducing neoangiogenesis within the EGF growth factor family, at least in GEO tumor xenografts. It has also been previously shown that neoangiogenesis, as well as VEGF and bFGF staining, were signi®cantly reduced in GEO tumor xenografts following treatment with an EGF receptor blocking antibody . Taken together, these data suggest that the anti-tumor eect of the MBOs directed against AR, CR and TGFa is due to two dierent mechanisms: (1) a direct inhibition of tumor cell growth, that is sustained by autocrine circuits involving the EGF-like peptides and their receptors; (2) a reduction of neoangiogenesis, that is induced by the EGF-like growth factors, either directly or indirectly through other factors such as VEGF or bFGF, and that is necessary for tumor growth. However, other mechanisms might be involved in the anti-tumor eects of the MBOs. In fact, we found that after termination of treatment, GEO tumors in AS treated mice resumed growth at a rate slightly slower as compared to that of controls. We might hypothesize that treatment with the AS oligonucleotides may select for tumor cells with a slower growth rate. In this regard, Ciardiello et al. (1996) found that GEO tumors in mice treated with an EGF-receptor blocking antibody and a PKA inhibitor resumed a growth rate similar to controls only after 60 days following the end of treatment. We could not follow the growth of the tumors for such a long period. In fact, we had to sacri®ce the mice 35 days following the end of the treatment for ethical reasons.
In conclusion, we have clearly demonstrated that AS MBOs directed against TGFa, AR and CR are able to inhibit the in vivo growth of human colon carcinoma cells. This study also suggests that the use of combinations of EGF-related MBOs might represent a novel, experimental therapeutic approach for the treatment of colon carcinomas. Since co-expression of dierent EGF-related growth factors also occurs in several other types of carcinoma, this approach might prove eective in the treatment of other cancers.
Materials and methods

Antisense oligonucleotides
Phosphorothioate and Mixed Backbone oligodeoxynucleotides were synthesized and puri®ed at Hybridon Inc. (Cambridge, MA, USA).
Cell culture
GEO cells were maintained in McCoy's medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 20 mM HEPES, pH 7.4, penicillin (100 U/ml), streptomycin (100 mg/ml) (Sigma, Milan, Italy). Growth factors were obtained from the following sources: recombinant AR from Sigma; recombinant TGFa from Collaborative Research; recombinant CR protein was synthesized in the laboratory of Dr DS Salomon (Seno et al., 1998) .
Clonogenic assays
GEO cells (5610 3 cells/well) were seeded in 0.3% Difco Bactoagar (Difco, Detroit, MI, USA) supplemented with complete culture medium. This suspension was layered over 0.5 ml of 0.8% agar-medium base layer in 24 multiwell cluster dishes (Becton Dickinson, Milan, Italy) . The cells were treated 2 h and 5 days after seeding with the indicated concentrations of antisense oligonucleotides. After 12 days, the colonies were stained with nitroblue tetrazolium, and colonies larger than 50 mm were acquired with a microScopeman camera system (Moritex Europe Ltd.), and analysed with Image-Pro Plus (Media Cybernetics) computer program.
Tumor xenografts
Tumors were established in nude mice by subcutaneous injection of 5610 6 GEO cells suspended in 0.2 ml of Matrigel (Beckton Dickinson) into the dorsal¯ank. Antisense oligonucleotides were administered by intraperitoneal injection. Mice were sacri®ced before tumors reached a volume of 2.5 cm 3 , for ethical reasons.
Western blot analysis
Whole protein extracts were prepared and analysed by Western blotting by using the chemiluminescence ECL Western blotting kit (Amersham, Milan, Italy), as previously described Normanno et al., 1996) . The following antibodies were used: (a) anity puri®ed, rabbit policlonal anti-AR Ab-2 antibody, kindly provided by Dr G Johnson (FDA, Bethesda, MD, USA); (b) rabbit policlonal anti-CR a-MS2 antibody, kindly provided by Dr R Harkins (Berlex Biosciences Inc., Richmond, CA, USA); (c) rabbit policlonal anti-TGFa antibody R9, kindly provided by Dr B Langton-Webster (Berlex Biosciences Inc.); (d) rabbit policlonal anti-phospho p44/p42 MAPK (New England Biolabs); (e) rabbit policlonal anti p44/p42 MAPK (New England Biolabs). Films were analysed using an ImageQuant densitometer.
Immunohistochemistry
Immunocytochemical analysis of TGFa, AR and CR expression in GEO tumor xenografts was performed as previously described . The antibodies used were the rabbit polyclonal AR-Ab1 anti-AR antibody, kindly provided by Dr Gibbes R Johnson (DCB, FDA, Bethesda, MD 20892, USA), or a rabbit polyclonal anti-CR antibody, kindly provided by Dr WJ Gullick (ICRF, London, UK), or the anti-TGFa monoclonal antibody Ab-2 (Oncogene Science). Non-speci®c staining was evaluated for each specimen using either a similar concentration of preimmune serum or IgG, or by absorbing the primary antibody with the appropriate speci®c immunogen. The slides were evaluated by three investigators blinded to the treatment (A D'Antonio, S Losito and N Normanno). Both intensity of staining and percentage of immunopositive cells were scored. Speci®c staining was semiquantitated by assigning a score of 0 to +++ based on color intensity of the brown diaminobenzidine precipitate, with + representing light brown staining; ++ a moderately brown color; and +++, an intense brown color. The results shown in Table 2 represent the average of the scores obtained by the three investigators. For microvessel count, tumors were stained with an anti-Factor VIII, rabbit polyclonal antibody (Dakopatts, Glostrup, Denmark). Each sample was determined under low power to identify the ®ve regions of the section with the highest number of microvessels. Microvessels were counted at high power (2506) in each of the ®ve ®elds. Large vessels with thick muscular walls were excluded from the counts.
Semi-quantitative reverse transcriptase-polymerase chain reaction (RT ± PCR)
Total cellular RNA from GEO tumor xenografts was obtained by the acid guanidine isothyocianate-phenol-chloro-form extraction procedure. RT ± PCR and Southern blot assay were performed as previously described (De Luca et al., 1999) . The membranes were hybridized with speci®c cDNA probes. The PCR product was visualized by using strepdavidin-peroxidase-coupled enhanced chemiluminescence (New England Biolabs). Films were analysed using an ImageQuant densitometer. The relative amount of TGFa, AR, CR and GAPDH mRNA in tumors from treated and untreated mice was assessed. Several dilutions of cDNA were assayed for each test group, in order to reach non-saturating concentrations of ampli®cation product in the RT ± PCR reaction. The average ratio between TGFa, AR, and CR transcripts' levels in treated vs untreated tumors was assessed, following normalization by GAPDH levels.
